40th week of 2014 patent applcation highlights part 63 |
Patent application number | Title | Published |
20140296131 | Truncated GLP-1 Derivatives and Their Therapeutical Use - The invention relates to truncated GLP-1 analogues, in particular a GLP-1 analogue which is a modified GLP-1(7-35) (SEQ ID No 1) having: i) a total of 2, 3, 4, 5 6, 7, 8, or 9 amino acid substitutions as compared to GLP-1(7-35), including a) a Glu residue at a position equivalent to position 22 of GLP-1(7-35), and b) an Arg residue at a position equivalent to position 26 of GLP-1(7-35); as well as derivatives thereof, and therapeutic uses and compositions. These analogues and derivatives are highly potent, have a good binding affinity to the GLP-1 receptor, also to the extracellular domain of the GLP-1 receptor, which is of potential relevance achieving long-acting, stable GLP-1 compounds with a potential for once weekly administration. | 2014-10-02 |
20140296132 | Anti-bacterial Polypeptides and Pathogen Specific Synthetic Antibodies - The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants. | 2014-10-02 |
20140296133 | SILA ANALOGS OF OXAZOLIDINONE DERIVATIVES AND SYNTHESIS THEREOF - The invention discloses silaanalogs of oxazolidinone compounds, to pharmaceutical compositions and to the synthesis of the oxazolidinone derivatives of formula I. The invention further relates to methods of treating a subject suffering with gram positive pathogens including those resistant to methicillin and vancomycin using the compound(s) or modulation of coagulation properties of blood-clotting cascade or compositions of the oxazolidinone derivatives of the invention. | 2014-10-02 |
20140296134 | METHODS AND USES FOR METABOLIC PROFILING FOR CLOSTRIDIUM DIFFICILE INFECTION - Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample. | 2014-10-02 |
20140296135 | MEDICAMENT FOR THE TREATMENT OF FUNGAL INFECTIONS PARTICULARLY ASPERGILLOSIS - The combination of pentraxin PTX3 with antifungals is described for the treatment of fungal infections and particularly for infections caused by | 2014-10-02 |
20140296136 | HCV NS3 PROTEASE INHIBITORS - The present invention relates to macrocyclic compounds of formula (I) that are useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, their synthesis, and their use for treating or preventing HCV infections. | 2014-10-02 |
20140296137 | METHODS AND COMPOSITIONS FOR CONTROLLING ROTIFERS - Described herein are compositions and methods for controlling, inhibiting, reducing and/or preventing rotifer growth with antimicrobial peptides. Methods for removing and/or preventing rotifer infestations in algae cultivations by controlling, inhibiting, reducing and/or preventing rotifer growth with an antimicrobial peptide (AMP) are further provided. Also described are transgenic algae comprising an expression vector comprising a nucleic acid sequence encoding an AMP. In some instances, the nucleic acid sequence encoding the AMP is codon-optimized for expression in algae. | 2014-10-02 |
20140296138 | METHODS AND COMPOSITIONS FOR CONTROLLING NEMATODE PESTS - Transgenic plants expressing a Vip3 protein have been found to be efficacious against plant-infesting nematodes. Disclosed are methods of controlling nematode populations using transgenic plants expressing Vip3 protein. | 2014-10-02 |
20140296139 | MITOCHONDRIAL-DERIVED PEPTIDE MOTS3 REGULATES METABOLISM AND CELL SURVIVAL - MOTS3 is a novel polypeptide. Methods of treating diseases such as diabetes, obesity, fatty liver, and cancer using MOTS3 and pharmaceutical compositions thereof are disclosed herein. | 2014-10-02 |
20140296140 | Equipment Assembly for and Method of Processing Particles - An equipment assembly for preparing, harvesting and collecting particles is disclosed. The assembly comprises a tandem filter system with one or more high pressure filters, one or more low pressure filters and one or more collection vessel. Particles can be prepared, harvested and collected continuously, semi-continuously or in a batch-type operation. A tandem filter system and its method of use are also disclosed. Particles made with the assembly and according the instant methods are also disclosed. The assembly provides improved particle harvesting and collection over other systems and permits continuous particle formation, in particular by dispersion of a solute-containing process fluid within a supercritical anti-solvent. | 2014-10-02 |
20140296141 | Compositions and Methods for Treating Obesity, Obesity Related Disorders and for Inhibiting the Infectivity of Human Immunodeficiency Virus - The present invention relates to methods and pharmaceutical compositions for treating obesity or obesity-related disorders in a subject suffering from or predisposed to developing obesity or an obesity-related disorder, or for inhibiting the infectivity of HIV, by administering oleuropein, an analogue or derivative thereof, or the major metabolites of oleuropein including oleuropein aglycone, hydroxytyrosol, and elenolic acid or their analogues, or derivatives thereof, an iridoid glycoside, or a secoiridoid glycoside or analogues or derivatives thereof, or any combination of the foregoing including olive leave extract. The invention also relates to methods for screening/diagnosing a subject having, or predisposed to having obesity or a related disorder by measuring the expression profiles of an adipogenic gene selected from PPARγ2, LPL and αP2 gene and gene product, or other adipogenic, lipogenic, or lipolytic genes and gene products in an individual. The invention further provides for screening for novel oleuropein analogues. | 2014-10-02 |
20140296142 | GENE THERAPY FOR DIABETIC NEUROPATHY USING AN HGF ISOFORM - The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy. | 2014-10-02 |
20140296143 | Angiotensin-(1-7) As A Chemoprevention Agent - Disclosed is the use of angiotensin-(1-7) peptide as an anti-cancer and chemoprevention therapeutic. Embodiments of the present invention comprise methods and compositions to prevent cancer or to reduce the risk of cancer in an individual comprising administering to the individual a pharmaceutically effective amount of an agonist for the angiotensin-(1-7) receptor to inhibit at least one of formation of a tumor (tumorigenesis), the proliferation of tumor cells, the growth of tumor cells, or metastasis of tumor cells in the individual. Cancers treated using the methods and compositions described herein may include cancers having an angiotensin-(1-7) receptor, including, but not limited to, breast cancer, colon cancer, glioblastoma, and lung cancer. | 2014-10-02 |
20140296144 | PROCESS FOR THE PREPARATION OF OCTREOTIDE ACETATE - The present invention relates to an improved process for large scale production of Octreotide acetate. The invention also relates to pharmaceutical composition of octreotide acetate. | 2014-10-02 |
20140296145 | Modified Human Growth Hormone Polypeptides and Their Uses - Modified human growth hormone polypeptides and uses thereof are provided. | 2014-10-02 |
20140296146 | Thermostable Inhibitors of Activation of the Blood Clotting System Through Contact with Foreign Surfaces - The present invention relates to the field of blood clotting. Specifically, the invention relates to particular inhibitors of artificial activation of the blood clotting process through contact with foreign surfaces. | 2014-10-02 |
20140296147 | METHODS OF TREATING OR PREVENTING BLOOD LOSS DURING SURGERY USING THE SERINE PROTEASE INHIBITOR MDCO-2010 - Methods of inhibiting, treating or preventing blood loss in a subject undergoing surgery through the administration of an effective amount of the novel serine protease inhibitor MDCO-2010 or its salts or esters are disclosed. | 2014-10-02 |
20140296148 | MEDICAMENT FOR THERAPEUTIC TREATMENT AND/OR IMPROVEMENT OF SEPSIS - A medicament for therapeutic treatment and/or improvement of sepsis in a patient with severe sepsis accompanied with one or more organ dysfunctions, wherein a value of International Normalized Ratio (INR) of a plasma specimen obtained from said patient is more than 1.4, which comprises thrombomodulin as an active ingredient. | 2014-10-02 |
20140296149 | Compositions and Methods for the Treatment of Cardiac Surgery-Associated Acute Kidney Injury with Annexin A1 Peptide - The present invention provides a method of treating, ameliorating and/or preventing cardiac surgery-associated acute kidney injury (AKI) in a subject, comprising administering to the subject a therapeutically effective amount of an ANXA1 peptide such that the AKI is treated, ameliorated and/or prevented. | 2014-10-02 |
20140296150 | Carrier-Linked Treprostinil Prodrugs - The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH). | 2014-10-02 |
20140296151 | PEPTIDES FROM FISH GELATINE - The invention relates to a process of preparing low molecular weight peptides from gelatine. The gelatine is broken down into low molecular weight peptides using enzymes from | 2014-10-02 |
20140296152 | Stem Cell Derived Factors for Treating Pathologic Conditions - A purified paracrine factor of a mesenchymal stem cell, such as a Secreted frizzled related protein (Sfrp) is useful to reduce cell death an/or tissue injury associated with ischemic conditions. | 2014-10-02 |
20140296153 | Oligodendrocyte Differentiation - The present invention provides compounds, compositions and methods for treatment and/or prevention of neurodegenerative diseases, including but not limited to autoimmune diseases, such as multiple sclerosis, in which demyelination, (the loss of the myelin sheath that insulates the nerves) is an associated or causative feature. The data provided demonstrate the utility of the compounds and compositions according to this invention to promote oligodendrogenesis and myelination or remyelination. | 2014-10-02 |
20140296154 | METHOD OF PREVENTING DEVELOPMENT OF PSORIATIC LESIONS - The present invention relates to a method of inhibiting onset of or preventing development of a psoriatic lesion in a patient having psoriasis. The method comprises administering to a patient having psoriasis an effective amount of an agent that inhibits NF-κB activity under conditions effective to inhibit onset of or prevent development of psoriatic lesions. Another aspect of the invention relates to a method of treating an early stage psoriatic lesion on a patient by contacting the early stage psoriatic lesion of a patient with an effective amount of an agent that inhibits NF-κB activity, whereby said contacting inhibits development of the early stage psoriatic lesion. Both transgenic and nontransgenic approaches are contemplated. | 2014-10-02 |
20140296155 | ANTI-STRETCH MARK SKIN CREAM AND METHOD FOR MAKING AND USING THEREOF - A skin cream and method for making and applying the skin cream having, e.g., a copper component, an ascorbic acid component, a lipid component and a peptide component. The peptide component can include palmitoyl pentapeptide (KTTLS) or hydrolized serecin. The copper component can be a copper solubilizing formulation. The copper solubilizing formulation can include one of (I) copper and a copper-complexing peptide and/or (ii) a copper-complexing protein. The combination of copper and the ascorbic acid component can prevent or reduce a destabilization of the ascorbic acid component. | 2014-10-02 |
20140296156 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 2014-10-02 |
20140296157 | COMPOSITIONS AND METHODS FOR PREPARING A SUBJECT FOR ORGAN OR NON-ORGAN IMPLANTATION - Embodiments of the present invention illustrate methods of preventing transplantation rejection. In certain embodiments, a subject in need of an organ or non-organ transplantation can be pretreated with an AAT composition to reduce the incidence of transplantion rejection in the subject. Other embodiments include treating a subject with a composition including AAT before, during or after plastic surgery. | 2014-10-02 |
20140296158 | SUSTAINED ACTION FORMULATION OF CYCLOSPORIN FORM 2 - Disclosed herein are methods of treating diseases of the eye by administering to the subconjunctival space a formulation comprising cyclosporin A form 2 and a hydrogel. | 2014-10-02 |
20140296159 | Method for Therapeutic Replenishment and Enrichment of Ocular Surface Lubrication - The present invention provides a pharmaceutical composition, and methods of use thereof, for treating ocular boundary deficiency, symptoms associated therewith, or undesired condition that is associated with or causes ocular boundary deficiency at the ocular surface. The pharmaceutical composition of the present invention comprises a human PRG4 protein, a lubricant fragment, homolog, or isoform thereof, suspended in an ophthalmically acceptable balanced salt solution. The pharmaceutical composition of the present invention may also comprise one or more ophthalmically acceptable agents selected from the group consisting of an ophthalmically acceptable demulcent, excipient, astringent, vasoconstrictor, emollient, sodium hyaluronate, hyaluronic acid, and surface active phospholipids, in a pharmaceutically acceptable carrier for topical administration. | 2014-10-02 |
20140296160 | STABILIZED ALPHA HELICAL PEPTIDES AND USES THEREOF - Novel polypeptides and methods of making and using the same are described herein. The polypeptides include cross-linking (“hydrocarbon stapling”) moieties to provide a tether between two amino acid moieties, which constrains the secondary structure of the polypeptide. The polypeptides described herein can be used to treat diseases characterized by excessive or inadequate cellular death. | 2014-10-02 |
20140296161 | DIDEMNIN BIOSYNTHETIC GENE CLUSTER IN TISTRELLA MOBILIS | 2014-10-02 |
20140296162 | Whey Protein Composition with a Reduced Astringency - The invention relates to a sterilized liquid or semi-solid acid enteral composition comprising per 100 ml 9 to 20 g of non-hydrolysed globular proteins, fat and at least 100 mg of divalent metal cations and having a pH ranging between 3 and 5. The invention further relates to a method for preparing a composition according to the invention, comprising a step wherein at least the non-hydrolysed globular proteins are subjected to a direct steam injection (DSI) at specific holding values, such as a holding temperature of 100 to 140° C. during a holding time of about 0.5 to 10 seconds, followed by a homogenization step and a sterilization step The composition according to the invention has a reduced astringency and can be used for medical purposes, such as for stimulating muscle protein synthesis in a mammal, in particular for treating sarcopenia, and for specific groups of people, such as elderly and sportsman. | 2014-10-02 |
20140296163 | Methods and Compositions for the Treatment of Gastrointestinal Disorders - Compositions and related methods for treating IBS and other gastrointestinal disorders and conditions (e.g., gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia (including functional dyspepsia or nonulcer dyspepsia), gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudoobstruction), and disorders and conditions associated with constipation, e.g., constipation associated with use of opiate pain killers, post-surgical constipation, and constipation associated with neuropathic disorders as well as other conditions and disorders are described. The compositions feature peptides that activate the guanylate cyclase C (GC-C) receptor. | 2014-10-02 |
20140296164 | Compositions and methods of use for cell targeted inhibitors of the Cystic Fibrosis transmembrane regulator associated ligand - The present invention describes peptide drugs that inhibit the interaction between CAL and CFTR, and other proteins in cystic fibrosis and other diseases. These invented drugs have been chemically optimized to impart solubility, stability, cell permeability, mucus penetration, intracellular targeting and sequestration, increased potency and non-immunogenicity, while conserving and imparting efficacy. This renders these compositions suitable for human use, which is exemplified by use in the treatment of cystic fibrosis. | 2014-10-02 |
20140296165 | USE OF TIGHT JUNCTION ANTAGONISTS TO TREAT INFLAMMATORY BOWEL DISEASE - The present invention provides materials and methods for the treatment of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis). Materials of the invention may include compositions comprising one or more tight junction antagonists and optionally one or more therapeutic agents. Methods of the invention may comprise treating a subject in need thereof with a composition comprising one or more tight junction antagonists and, optionally one or more therapeutic agents. | 2014-10-02 |
20140296166 | BISPHOSPHONATE COMPOSITIONS AND METHODS FOR TREATING AND\OR REDUCING CARDIAC DYSFUNCTION - The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analogue or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject. | 2014-10-02 |
20140296167 | GLYCOSYLATION SITE-SPECIFIC ANTIBODIES AND ANTI-CANCER COMPOUNDS - A method of characterizing the protein O-GlcNAcylation site-specificity of an antibody. A method of detecting or quantitating the expression of site-specific O-GlcNAcylated proteins expressed in cells and biological samples. A method of diagnosing cancer in a host based on the cellular expression of site-specific O-GlcNAcylated proteins. A method of screening anti-cancer compounds according to their ability to increase a level O-GlcNAcylation of oncogene or tumor suppressor proteins. Methods of treating cancer in an animal host by administering compounds that increase a level of O-GlcNAcylated c-myc or p53 in cancer cells. A method of distinguishing subclasses of pancreatic cancer according to the sensitivity of pancreatic cancer cells to an imidazole derivative, and a method of personalized pancreatic cancer treatment delivered according to the sensitivity subclasses. | 2014-10-02 |
20140296168 | MIXTURE COMPOSITION COMPRISING RHAMNOLIPIDS - The invention relates to a mixture composition comprising rhamnolipids, to a process for its preparation, to its use for producing formulations and to formulations comprising this mixture composition. | 2014-10-02 |
20140296169 | ISOTHIAZOLOPYRIDINE-2-CARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS - The present disclosure relates to substituted isothiazolo[5,4-b]pyridine-2-carboxamides of the formula I, | 2014-10-02 |
20140296170 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF BONE DISEASES COMPRISING SPINASTEROL GLUCOSIDE DERIVATIVE - Disclosed is a pharmaceutical composition for the prevention or treatment of metabolic bone diseases, comprising a spinasterol glucoside derivative, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof. The pharmaceutical composition is effectively useful for preventing or treating metabolic bone diseases. | 2014-10-02 |
20140296171 | NOVEL UREA COMPOUNDS - The present invention provides a compound of Formula I: | 2014-10-02 |
20140296172 | Method for screening compounds comprising the use of picornavirus protease 2A - A method of screening compounds or molecules comprising the steps of: translating a sequence encoding the amino acid sequence comprising SEQ ID No. 29 in a translation system in the presence of a test compound or molecule; and analysing the translation product(s) for the presence of one or more of (a) a peptide comprising the amino acids Pro-Gly at the C terminus and a peptide comprising the amino acid Pro at the N terminus: or (b) a peptide comprising the amino acid sequence of SEQ ID No. 29. | 2014-10-02 |
20140296173 | STABLE NANOCOMPOSITION COMPRISING EPIRUBICIN, PROCESS FOR THE PREPARATION THEREOF, ITS USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT - A nanoparticulate composition is disclosed for the targeted therapeutic treatment of tumours. The stable self assembled nanocomposition according to the invention comprises (i) a carrier and targeting system comprising an optionally modified polyanion, and optionally a polycation, which may also be modified; at least one targeting agent which is linked to either the polycation/modified polycation or the polyanion/modified polyanion, or both; (ii) an active compound selected from the group of epirubicin and its pharmaceutically acceptable salts, especially hydrochloride; and optionally (iii) at least one complexing agent, metal ion and stabilizer/formulating agent. The invention furthermore relates to a process for the preparation of the above-mentioned composition, the therapeutic uses thereof, and pharmaceutical compositions containing the nanocomposition according to the invention. | 2014-10-02 |
20140296174 | SILK-BASED MULTIFUNCTIONAL BIOMEDICAL PLATFORM - The present invention provides a multifunctional platform suitable for biomedical applications. In particular, the invention includes a silk fibroin-based multifunctional device that enables both the sustained delivery of a drug and monitoring of such delivery in vivo. | 2014-10-02 |
20140296175 | COMPOSITION AND METHOD FOR INDUCING EPO-MEDIATED HAEMOGLOBIN EXPRESSION AND MITOCHONDRIAL BIOGENESIS IN NONHAEMATOPOIETIC CELL - A composition for inducing erythropoietin (EPO)-mediated haemoglobin (Hb) expression in a nonhaematopoietic cell of a subject is provided. The composition includes a compound represented by formula (I), wherein R is a glycosyl group; and a pharmaceutical acceptable carrier. | 2014-10-02 |
20140296176 | COMBINATION CANCER THERAPY WITH AN HSP90 INHIBITOR AND AN ANTIMETABOLITE - The invention provides a method of treating a subject with cancer, particularly leukemia, lymphoma, solid cancer such as colorectal cancer, gastric cancer, bladder cancer, non-small cell lung cancer, and breast cancer, comprising administering to the subject a compound of formulae (I) 40 or (Ia) in combination with an antimetabolite such as methotrexate, pemetrexed, cytarabine or nelarabine, or 5-fluorouracil, or capecitabine or their derivatives. | 2014-10-02 |
20140296177 | NOVEL ANTIMICROBIAL COMPOUNDS - A new class of biotin protein ligase (BPL) inhibitors that have antibacterial activity against multiple | 2014-10-02 |
20140296178 | Combination Therapy with a Gallium Complex - A combination therapy is disclosed for treating cancer. The method comprises identifying a patient diagnosed of cancer and in need of treatment, administering to a cancer patient a therapeutically effective amount of a compound of Formula (I), and administering to said patient a therapeutically effective amount of a certain second anti-cancer drug. | 2014-10-02 |
20140296179 | NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS AND OLIGOSACCHARIDES - The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows. | 2014-10-02 |
20140296180 | CYCLIC OLIGOSACCHARIDES FOR USE IN THE TREATMENT AND PREVENTION OF BACTERIAL INFECTION - Compounds which inhibit Wza-mcdiated polysaccharide transport are useful in the prevention or treatment of bacterial infection, in particular of | 2014-10-02 |
20140296181 | METHODS OF MODULATING ONCOGENIC FUSION PROTEINS - Described herein, at least in part, are methods of modulating oncogenic fusion proteins. | 2014-10-02 |
20140296182 | METHOD AND COMPOSITION FOR TREATING LICE INFESTATION - Methods and compositions for the treatment of pediculosis comprising: between 1 and 20% (w/w) isopropyl myristate; between 1 and 20% (w/w) silicone oil; and at least 20% (w/w) water. Methods and compositions for dissolving nit glue comprising at least three components selected from the group consisting of benzyl alcohol, diacetone alcohol, acetic acid, and triethyl citrate | 2014-10-02 |
20140296183 | AMINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES - A novel amine compound represented by the following formula (I), which is superior in immunosuppressive action, rejection suppressive action and the like, and shows reduced side effects such as bradycardia and the like, or a pharmaceutically acceptable acid addition salt thereof, or hydrates thereof, or solvate, as well as a pharmaceutical composition containing this compound and a pharmaceutically acceptable carrier. | 2014-10-02 |
20140296184 | SILYLATED AZULENYL NITRONE SPIN TRAPS AS CHROMOTROPIC SUPEROXIDE DETECTORS - Silylated nitrones and methods of detecting and/or superoxide using silylated nitrones are disclosed herein. | 2014-10-02 |
20140296185 | Solid formulations suitable for oilfield applications - The present invention relates to a solid formulation of soap stick type comprising a primary surfactant, at least one binding agent and at least one dispersant that may especially be an amphoteric surfactant, optionally with additives. | 2014-10-02 |
20140296186 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY - The present invention relates to substituted triazole compounds and compositions comprising substituted triazole compounds. The invention further relates to methods of inhibiting the activity of Hsp90 in a subject in need thereof and methods for preventing or treating hyperproliferative disorders, such as cancer, in a subject in need thereof comprising administering to the subject a substituted triazole compound of the invention, or a composition comprising such a compound. | 2014-10-02 |
20140296187 | METHODS FOR THE SYNTHESIS OF PLASMALOGENS AND PLASMALOGEN DERIVATIVES, AND THERAPEUTIC USES THEREOF - A method for preparing plasmalogens and derivatives thereof represented by Formula B, wherein R1 and R2 are similar or different, derived from fatty acids; R3 is selected from hydrogen and small alkyl groups. The synthetic route involves production of novel cyclic plasmalogen precursors of Formula A and their conversion to plasmalogens and plasmalogen derivatives of Formula B. Also disclosed is the therapeutic use of plasmalogens and derivatives thereof as produced by the synthetic route of the present invention. | 2014-10-02 |
20140296188 | NEW THERAPY FOR TRANSTHYRETIN-ASSOCIATED AMYLOIDOSIS - It is provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of trans-thyretin-associated amyloidosis. It is also provided a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of transthyretin-associated amyloidosis in combination therapy with another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate. | 2014-10-02 |
20140296189 | INTRAVENOUS FORMULATION WITH WATER-SOLUBLE COCRYSTALS OF ACETYLSALICYLIC ACID AND THEANINE - A method of reducing niacin flushing in a subject using a water-soluble cocrystal composition which contains a quantity of acetylsalicylic acid and a quantity of a theanine enantiomer. | 2014-10-02 |
20140296190 | MARKETING THE USE OF 25-HYDROXYVITAMIN D3 TO ENHANCE COGNITION - This invention relates to a method of marketing 25-hydroxyvitamin D3 (25-OH D3) comprising providing an effective dose of 25-OH D3 and informing the potential consumer that it is beneficial for increasing or maintaining executive functioning, or lessening the decrease of cognitive functioning. Kits containing the 25-OH D3 and information regarding its benefits in this area are also part of this invention. | 2014-10-02 |
20140296191 | COMPOSITIONS OF PHARMACEUTICAL ACTIVES CONTAINING DIETHYLENE GLYCOL MONOETHYL ETHER OR OTHER ALKYL DERIVATIVES - The present invention relates to pharmaceutical compositions of various pharmaceutical actives, especially lyophilic and hydrophilic actives containing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle and/or to pharmaceutical compositions utilizing Diethylene glycol monoethyl ether or other alkyl derivatives thereof as a primary vehicle or as a solvent system in preparation of such pharmaceutical compositions. The pharmaceutical compositions of the present invention are safe, non-toxic, exhibits enhanced physical stability compared to conventional formulations containing such pharmaceutical actives and are suitable for use as injectables for intravenous and intramuscular administration, as well as for use as a preformed solution/liquid for filling in and preparation of capsules, tablets, nasal sprays, gargles, dermal applications, gels, topicals, liquid oral dosage forms and other dosage forms. | 2014-10-02 |
20140296192 | PHARMACEUTICAL COMPOSITION FOR USE IN NASAL ADMINISTRATION CONTAINING CORTICOID, AND A QUINOLONE OR FUSIDIC ACID - The invention relates to a pharmaceutical composition of unit dose for inhalation by a human subject comprising a topical corticoid and a quinolone or fucidic acid, characterized in that the ratio of the weight of the topical corticoid to the weight of the quinolone or fucidic acid is between 0.02 and 20 and the amount of quinolone or of fucidic acid is less than 1 mg. This composition can be administered by nasal spray and is used for treating the upper and lower respiratory tract, in particular sinusitis and nasal polyps. | 2014-10-02 |
20140296193 | MULTIPHASIC CONTRACEPTIVE REGIMEN FOR ORAL COMBINATION DRUG FORMULATION OF PROGESTIN AND ESTROGEN - A method of contraception in a female is provided. The method includes administering to the female daily for a first number of successive days an oral combination drug formulation of a progestin and an estrogen. The oral combination drug formulation is administered in a multiphasic dosing regimen comprising a second number of phases with duration of each phase is a third number of days. The doses of each of the progestin and estrogen in each subsequent phase of the regimen increase by a predefined dose increment as compared to the corresponding doses of the progestin and estrogen administered during immediately preceding phase of the regimen. The ratio of a daily dose of progestin to a daily dose of estrogen is maintained at a constant level during the entire dosing period. The first number of successive days period is followed by a fourth number of days without progestin and estrogen administration. | 2014-10-02 |
20140296194 | PREVENTION OR ATTENUATION OF NEUROPATHIC PAIN AND KIDNEY INJURY BY TAUROURSODEOXYCHOLIC ACID - Methods of reducing or abolishing neuropathic pain in humans and animals are discussed. In some examples administration of the apoptosis inhibitor taurours-odeoxycholic acid (TUDCA), greatly reduced both neuronal loss and the increase in glia, and partially reversed spinal nerve ligation (SNL)-induced mechanical hypersensitivity. Among RVM neurons, serotonergic (5-HT) neurons decreased by 35% ipsilateral to SNL. In some examples, the density of 5-HT immunoreactive varicosities in the superficial dorsal horn of the spinal cord was lower ipsilateral to SNL. The RVM 5-HT neurons that remained after SNL appeared to facilitate nociception. When rats that had undergone SNL were treated with the 5-HT neurotoxin, 5,7-dihydroxytryptamine (5,7-DHT), mechanical withdrawal thresholds increased significantly. In some examples nerve injury induces death of antinociceptive RVM neurons which can be reduced or abolished by TUDCA. In some examples, that the loss of RVM neurons shifts the balance of descending control from pain inhibition to pain facilitation. | 2014-10-02 |
20140296195 | METHOD FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM CANCERS AND COMPOSITIONS RELATED THERETO - Use of compounds disclosed herein, typically progesterone or analog or derivative thereof, in the treatment of central nervous system cancers, specifically neuroblastoma and glioblastoma is provided. The treatment offers a reduced toxicity as compared to the currently available chemotherapeutic agents. The progesterone may be administered alone or in combination with, or in conjunction with other therapeutic agents. | 2014-10-02 |
20140296196 | NK1 ANTAGONISTS - A compound having the general structure shown in Formula I: | 2014-10-02 |
20140296197 | COMBINATIONS COMPRISING ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS - Combinations comprising (a) a β2 agonist and (b) an antagonist of M3 muscarinic receptors which is 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane, in the form of a salt having an anion X, which is a pharmaceutically acceptable anion of a mono or polyvalent acid are useful, e.g., for the treatment of respiratory disease, e.g., asthma or chronic obstructive pulmonary disease. | 2014-10-02 |
20140296198 | Assay For Predictive Biomarkers Of Anti-Estrogen Efficacy - Biomarkers associated with anti-estrogen sensitivity in cancers, methods for detecting and quantitating the biomarkers, and methods for treating cancer patients that exhibit the biomarkers are provided. The biomarkers are activated estrogen receptor foci (AEF) found in the nuclei of certain tumor cells. The methods provide new information to guide the intention to treat patients with anti-estrogens, allowing selection of individual patients and patient populations that are likely to respond to treatment. Also provided are methods for screening an antitumor drug or antitumor drug candidate for AEF inactivating activity. Such methods are useful to identify additional AEF-active drugs, including anti-estrogens, which may be candidates for use in treating AEF-positive tumors according to the methods of the invention. | 2014-10-02 |
20140296199 | PHARMACEUTICAL DELIVERY SYSTEMS FOR HYDROPHOBIC DRUGS AND COMPOSITIONS COMPOSITIONS COMPRISING SAME - A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided. | 2014-10-02 |
20140296200 | 6-(5-HYDROXY-1H-PYRAZOL-1-YL)NICOTINAMIDE INHIBITORS OF PHD - The present invention provides compounds of the formula: | 2014-10-02 |
20140296201 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION - Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): | 2014-10-02 |
20140296202 | SUBSTITUTED PIPERIDINYL COMPOUNDS USEFUL AS GPR119 AGONISTS - Substituted piperidinyl compounds of the formula (I): are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. Pharmaceutically acceptable salts are included as well. The compounds are useful as agonists of the g-protein coupled receptor GPR-119. | 2014-10-02 |
20140296203 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS - Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1). | 2014-10-02 |
20140296204 | CHEMICAL COMPOUNDS - The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula Q: | 2014-10-02 |
20140296205 | SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF - The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc. | 2014-10-02 |
20140296206 | COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT - Compounds and compositions useful for treating disorders related to Kit are described herein. | 2014-10-02 |
20140296207 | HETEROCYCLIC COMPOUNDS AND USES THEREOF - Heterocyclic entities that modulate PI3 kinase activity, pharmaceutical compositions containing the isoquinolone entities, and methods of using these chemical entities for treating diseases and conditions associated with P13 kinase activity are described herein. | 2014-10-02 |
20140296208 | KINASE INHIBITORS - There are provided compounds of formula I, | 2014-10-02 |
20140296209 | COMPOUNDS AND METHODS FOR TREATMENT OF HYPERTENSION - Hydrogenated pyrido[4,3-b]indoles, pyrido[3,4-b]indoles and azepino[4,5-b]indoles are described. The compounds may bind to and are adrenergic receptor α | 2014-10-02 |
20140296210 | PHARMACOLOGICAL TREATMENT OF COGNITIVE IMPAIRMENT - Methods for treating an individual to improve cognitive function are provided. In the subject methods, an effective amount of a noncompetitive GABA | 2014-10-02 |
20140296211 | ANAVEX2-73 AND CERTAIN ANTICHOLINESTERASE INHIBITORS COMPOSITION AND METHOD FOR NEUROPROTECTION - This invention concerns a dosage form comprising a therapeutically neuroprotective amount of A2-73 and a neuroprotective amount of at least one cooperating acetylcholinesterase inhibitor selected from the group consisting of donepezil, galantamine, rivastigmine, or memantine and method of use. | 2014-10-02 |
20140296212 | SUBSTITUTED PHENOXYPROPYLCYCLOAMINE DERIVATIVES AS HISTAMINE-3 (H3) RECEPTOR LIGANDS - The present invention provides compounds of formula I: | 2014-10-02 |
20140296213 | NEW POLYMORPH - The invention provides a new polymorph of 1-(2-methyl-4-(2,3,4,5-tetrahydro-1-benzazepin-1-ylcarbonyl)benzyl-carbamoyl)-L-proline-N,N-dimethylamide, pharmaceutical compositions containing it and its use in therapy. | 2014-10-02 |
20140296214 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor XIa and/or plasma kallikrein which may be used as medicaments. | 2014-10-02 |
20140296215 | Cyanoquinoline Compounds Having Activity in Correcting Mutant-Cftr Processing and Increasing Ion Transport and Uses Thereof - The present disclosure provides pharmaceutical compositions, pharmaceutical preparations and methods for increasing activity of a mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR). The pharmaceutical compositions, pharmaceutical preparations and methods are useful for the study and treatment of disorders associated with mutant-CFTR, such as cystic fibrosis. The pharmaceutical compositions and pharmaceutical preparations may include one or more cyanoquinoline-containing compounds of the embodiments, or an analog or derivative thereof. | 2014-10-02 |
20140296216 | PYRIMIDO[4,5-D]PYRIMIDINYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF - A compound of formula (I) or (II) and use of the compound in the preparation of drugs for treating cancer are disclosed. The study shows that the compounds can inhibit the growth of many kinds of tumor cells, can be used for targeting epidermal growth factor receptor (EGFR), and particularly can inhibit tumor cells with single or multiple mutations of EGFR (T790M). Therefore, the compound can be used as EGFR inhibitor to treat cancer and has a relatively large application value. | 2014-10-02 |
20140296217 | MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES - The present invention relates to the use of indolinones of general formula | 2014-10-02 |
20140296218 | SUPER-ENHANCERS AND METHODS OF USE THEREOF - The present invention relates in some aspects to super-enhancers and related compositions, methods, and agents that are useful for modulating expression of cell type-specific genes that are required for maintenance of cell identity (e.g., embryonic stem cell identity) or maintenance of a disease state (e.g., cancer). | 2014-10-02 |
20140296219 | COMPOUNDS FOR MODULATING TLR2 - The present invention is directed to methods, kits, and uses of inhibitors of LCMV mediated NF-κB activation to treat viral infections and inflammatory conditions. | 2014-10-02 |
20140296220 | PYRIDAZINO[4,5-D]PYRIMIDIN-5(6H)-ONE INHIBITORS OF KINASES - The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, | 2014-10-02 |
20140296221 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): | 2014-10-02 |
20140296222 | IMINOTHIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): | 2014-10-02 |
20140296223 | METHOD FOR REGULATING SKIN PIGMENTATION - This invention relates to a method for regulating skin pigmentation of a subject, comprising the step of administering the agent for inhibiting the expression or activation of Microphthalmia Transcription Factor (MITF) to the subject who is in need of regulation of skin pigmentation. | 2014-10-02 |
20140296224 | QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS - Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives. | 2014-10-02 |
20140296225 | Inhibitors of the Renal Outer Medullary Potassium Channel - The present invention provides compounds of Formula I | 2014-10-02 |
20140296226 | Amino-Oxazine and Amino-Dihydrothiazine Compounds as Beta-Secretase Modulators and Methods of Use - The present invention comprises a new class of compounds useful for the modulation of Beta-secretase enzyme activity and for the treatment of Beta-secretase mediated diseases, including Alzheimer's disease (AD) and related conditions. In one embodiment, the compounds have a general Formula I wherein A | 2014-10-02 |
20140296227 | APOPTOSIS INDUCING COMPOUNDS - The present invention relates to compounds of formula (I), wherein R | 2014-10-02 |
20140296228 | INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of formula I: | 2014-10-02 |
20140296229 | INDOLINONE ANALOGUES - The present invention encompasses compounds of general formula (I) | 2014-10-02 |
20140296230 | DIHYDROQUINAZOLINONE ANALOGUES - The present invention encompasses compounds of general formula (I) | 2014-10-02 |